Categories
Announcements Find Funding

Research Matters

NIH Funding Opportunities from the Illuminating the Druggable Genome Program

The NIH Common Fund’s Illuminating the Druggable Genome Program has issued two Funding Opportunity Announcements and a Notice of Special Interest to support research to advance understanding of poorly characterized proteins.

The NIH Common Fund’s Illuminating the Druggable Genome (IDG) Program has issued two Funding Opportunity Announcements and a Notice of Special Interest. Each of these funding opportunities will support research to advance understanding of poorly characterized proteins.

RFA-RM-21-012: Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)

Pilot projects will generate additional data and tools around understudied proteins identified by the IDG program (non-olfactory GPCRs, protein kinases, and ion channels) to elucidate the function of these proteins in the context of human disease.

Deadline: July 15, 2021 

RFA-RM-21-020: Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed)

This initiative will build Cutting Edge Informatics Tools (CEITs) that will support the IDG Consortium by (1) developing and deploying tools to enhance the community’s ability to process, analyze, and visualize IDG data, (2) prioritizing new data resources and methods to be incorporated into Pharos (https://pharos.nih.gov/) that will strengthen predictions about physiological and disease associations around IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels), and (3) developing methods to prioritize IDG-eligible understudied proteins for deeper study using experimental assays both developed within the IDG pipeline or by the larger community.

Deadline: July 15, 2021

The NIH will conduct a technical assistance pre-application webinar for investigators who are planning to submit an application in response to RFA-RM-21-020 and NOT-RM-21-019 on May 26, 2021, at 11 a.m. EST. Please use this link (https://nih.zoomgov.com/j/1611676153?pwd=d2hJRTlwenl2V1F6eVU5VUJMTDFXUT09) to participate. The intent of the webinar is to provide prospective applicants with information on the IDG Program and to address questions pertinent to preparing applications. The webinar is optional and not required for application submission. No pre-registration is required, but questions will be taken in advance and can be sent to DruggableGenome@mail.nih.gov. The webinar will be recorded and archived for viewing.

NOT-RM-21-019: Notice of Special Interest (NOSI) for Illuminating the Druggable Genome (IDG) Initiative: Request for Administrative Supplements to Existing Grants for Incorporating Single Cell Data into the IDG Knowledgebase

The IDG Pharos (https://pharos.nih.gov) resource and its underlying infrastructure manage knowledge about human proteins by accruing and abstracting data and information available in the primary literature, databases, and other resources around the world to create an integrated resource. Supplements to current NIH projects generating relevant single-cell data will enable those investigators to add it to Pharos. A major goal of the resource is to help the community prioritize and study understudied targets to determine their relevance in human health and disease.

Deadline: June 15, 2021 

The goal of the IDG program is identify and provide information on proteins that are currently not well studied within commonly drug-targeted protein families. For more details about the program visit the IDG website. For questions about these funding opportunities, contact DruggableGenome@mail.nih.gov.

The NIH Common Fund encourages collaboration and supports a series of exceptionally high impact, trans-NIH programs. These programs are supported by the Common Fund and managed by the NIH Office of the Director in partnership with the various NIH Institutes, Centers, and Offices.